Olaparib

Global $6.7 Bn Ovarian Cancer Opportunity Analysis and Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 5, 2019
Health, Pharmaceutical, Organic compounds, PARP inhibitors, Chemical compounds, Heterocyclic compounds, Lactams, RTT, Indoles, Gynaecology, Olaparib, Rucaparib, Cancer, Niraparib

The "Ovarian Cancer: Opportunity Analysis and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ovarian Cancer: Opportunity Analysis and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The dramatic growth in the ovarian cancer market is largely attributed to the label expansions for PARP inhibitors such as Lynparza, Zejula and Rubraca.
  • In 2028, three PARP inhibitor drugs are expected to have combined revenue of $2.8bn, constituting more than 40% of the global ovarian cancer market.
  • Analysis of the current and future market competition in the global ovarian cancer market.

Growth of PARP (Poly ADP-ribose Polymerase) Inhibitors Market to be Impacted by Expanded Application of PARP Inhibitors | Technavio

Retrieved on: 
Friday, October 18, 2019
Pharmaceutical, Health, Oncology, Branches of biology, Enzymes, Biology, Programmed cell death, PARP, Nucleotides, Poly (ADP-ribose) polymerase, PARP inhibitors, Adenosine diphosphate ribose, Poly(ADP-ribose) glycohydrolase, Olaparib, Parthanatos

PARP (Poly ADP-ribose Polymerase) Inhibitors Market Landscape 2019-2023: Geographic landscape

Key Points: 
  • PARP (Poly ADP-ribose Polymerase) Inhibitors Market Landscape 2019-2023: Geographic landscape
    PARP (Poly ADP-ribose Polymerase) Inhibitors Market Landscape 2019-2023: Indication
    Register for a free trial today and gain instant access to 10,000+ market research reports.
  • PARP inhibitors are known for their high efficacy in the treatment of diseases such as solid tumors.
  • Vendors save on R&D costs by incorporating single molecule of these inhibitors for conducting multiple pre-clinical and clinical trial studies.
  • The vast application landscape of PARP inhibitors encourages vendors to carry out research activities for new cancer indications.

Synthetic Lethality-based Drugs and Targets Market, 2019-2030

Retrieved on: 
Tuesday, October 1, 2019
Branches of biology, Biology, Programmed cell death, Cellular processes, DNA repair, Poly (ADP-ribose) polymerase, Synthetic lethality, PARP, Olaparib

, ,

Key Points: 
  • , ,
    Currently, there are four approved (and marketed) poly-ADP ribose polymerase (PARP) inhibitor drugs, which have been shown to operate based on the concept of synthetic lethality.
  • Further, several such drugs are being investigated for the treatment of a myriad of advanced oncological and non-oncological indications.
  • The 'Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways' report features an extensive study of the current market landscape and the future potential of the synthetic lethality-based therapeutics.
  • Further, it highlights the long-term opportunities (for drug developers) associated with individual targets, based on their popularity across different portals.

Synthetic Lethality-based Drugs and Targets Market, 2030

Retrieved on: 
Monday, September 30, 2019
Branches of biology, Biology, Programmed cell death, Cellular processes, Genetics, Synthetic lethality, Poly (ADP-ribose) polymerase, PARP inhibitor, PARP, DNA repair, Olaparib, Oncogenomics

DUBLIN, Sept. 30, 2019 /PRNewswire/ -- The "Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 30, 2019 /PRNewswire/ -- The "Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways" report has been added to ResearchAndMarkets.com's offering.
  • The Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways' report features an extensive study of the current market landscape and the future potential of the synthetic lethality-based therapeutics.
  • Currently, there are four approved (and marketed) poly-ADP ribose polymerase (PARP) inhibitor drugs, which have been shown to operate based on the concept of synthetic lethality.
  • One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for synthetic lethality-based drugs, over the next decade.

Global Synthetic Lethality-based Drugs and Targets Market Report 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways - ResearchAndMarkets.com

Retrieved on: 
Monday, September 30, 2019
Health, Pharmaceutical, Branches of biology, Biology, Programmed cell death, Cellular processes, Poly (ADP-ribose) polymerase, Synthetic lethality, PARP inhibitor, PARP, DNA repair, Olaparib, Parthanatos

The "Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways" report has been added to ResearchAndMarkets.com's offering.
  • The Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways' report features an extensive study of the current market landscape and the future potential of the synthetic lethality-based therapeutics.
  • Currently, there are four approved (and marketed) poly-ADP ribose polymerase (PARP) inhibitor drugs, which have been shown to operate based on the concept of synthetic lethality.
  • Further, several such drugs are being investigated for the treatment of a myriad of advanced oncological and non-oncological indications.

LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer

Retrieved on: 
Saturday, September 28, 2019
Biotechnology, FDA, General Health, Health, Pharmaceutical, Oncology, Genetics, Clinical trials, Clinical medicine, Medicine, Cancer, Cancer treatments, RTT, Oncology, Angiogenesis inhibitors, Genentech, Bevacizumab, Olaparib, Ovarian cancer, Chemotherapy, PAOLA-1, LYNPARZA, ovarian cancer, homologous recombination deficiency (HRD), BRCA Mutations, the AstraZeneca and Merck strategic oncology collaboration, AstraZeneca in Oncology, AstraZeneca

Overall Grade 3 or above adverse events (AEs) were 57% for LYNPARZA added to bevacizumab and 51% for bevacizumab alone.

Key Points: 
  • Overall Grade 3 or above adverse events (AEs) were 57% for LYNPARZA added to bevacizumab and 51% for bevacizumab alone.
  • AEs led to dose interruption in 54% of patients on LYNPARZA while 20% of patients discontinued treatment.
  • LYNPARZA is currently approved as 1st-line maintenance treatment in women with somatic and germline BRCA-mutated advanced ovarian cancer following response to platinum-based chemotherapy.
  • For 1st-line maintenance in advanced ovarian cancer and the metastatic breast cancer setting, physicians should select patients for therapy based on an FDA-approved companion diagnostic.

LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer

Retrieved on: 
Saturday, September 28, 2019
Research, Clinical trials, Biotechnology, Pharmaceutical, Health, Oncology, Science, Clinical medicine, Medicine, Cancer, RTT, Cancer treatments, Oncology, Bevacizumab, Genentech, Ovarian cancer, PARP inhibitor, Olaparib, Chemotherapy, PAOLA-1, LYNPARZA® (olaparib), Ovarian Cancer, Homologous Recombination Deficiency (HRD), GINECO, ENGOT, GCIG, the AstraZeneca and Merck Strategic Oncology Collaboration, Merck

Overall Grade 3 or above (AEs) were 57% for LYNPARZA added to bevacizumab and 51% for bevacizumab alone.

Key Points: 
  • Overall Grade 3 or above (AEs) were 57% for LYNPARZA added to bevacizumab and 51% for bevacizumab alone.
  • It is approved in the U.S. as first-line maintenance treatment in BRCAm advanced ovarian cancer following response to platinum-based chemotherapy.
  • LYNPARZA is the only PARP inhibitor with positive Phase 3 trials in four different cancer types.
  • Ovarian cancer the eighth most common cause of death from cancer in women worldwide, with a five-year survival rate of approximately 19%.

Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors

Retrieved on: 
Monday, September 9, 2019
Chemical compounds, Organic compounds, Amides, Piperazines, Lactams, Cyclacel, Breakthrough therapy, Genentech, Sapacitabine, 7+3, Olaparib, Chemotherapy regimen

We are excited to report that the first patient has been treated with oral CYC065 in part 3 of our Phase 1 study, said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.

Key Points: 
  • We are excited to report that the first patient has been treated with oral CYC065 in part 3 of our Phase 1 study, said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.
  • We look forward to reporting data from Part 2 and 3 of this study in 2020.
  • The DNA damage response program is evaluating an oral combination regimen of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS.
  • An IST is evaluating an oral combination regimen of sapacitabine and olaparib in patients with BRCA mutant breast cancer.

LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer

Retrieved on: 
Wednesday, August 14, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Drugs, RTT, Bevacizumab, Ovarian cancer, Olaparib, BRCA, Draft:SEE-FIM Protocol, Triple-negative breast cancer, PAOLA-1, LYNPARZA® (olaparib), Ovarian Cancer, GINECO, ENGOT, GCIG, the AstraZeneca and Merck Strategic Oncology Collaboration, Merck

The trial, in the first-line maintenance setting, compared LYNPARZA added to standard-of-care bevacizumab versus bevacizumab alone in women with or without BRCA-gene mutations.

Key Points: 
  • The trial, in the first-line maintenance setting, compared LYNPARZA added to standard-of-care bevacizumab versus bevacizumab alone in women with or without BRCA-gene mutations.
  • PAOLA-1 is the second positive Phase 3 trial with LYNPARZA in first-line advanced ovarian cancer.
  • Following positive results from the SOLO-1 trial for women with a BRCA gene mutation, the PAOLA-1 trial marks yet another positive Phase 3 trial for LYNPARZA as a first-line maintenance treatment for women with advanced ovarian cancer.
  • In this co-operative group trial sponsored by ARCAGY Research, maintenance treatment with LYNPARZA when added to a standard-of-care treatment was evaluated in an environment representative of real clinical practice.

LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer

Retrieved on: 
Wednesday, August 14, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer, Organic compounds, Chemical compounds, Oncology, Lactams, PARP inhibitors, Gynaecology, Ovarian cancer, RTT, Olaparib, Chemotherapy, Rucaparib, PAOLA-1, LYNPARZA, ovarian cancer, BRCA Mutations, the AstraZeneca and Merck strategic oncology collaboration, AstraZeneca in Oncology, AstraZeneca

PAOLA-1 is the second positive Phase III trial with LYNPARZA in 1st-line advanced ovarian cancer.

Key Points: 
  • PAOLA-1 is the second positive Phase III trial with LYNPARZA in 1st-line advanced ovarian cancer.
  • Following positive results from the SOLO-1 trial for women with a BRCA gene mutation, the PAOLA-1 trial marks yet another positive Phase III trial for LYNPARZA as a 1st-line maintenance treatment for women with advanced ovarian cancer.
  • LYNPARZA is currently approved as first-line maintenance treatment in BRCAm advanced ovarian cancer following response to platinum-based chemotherapy.
  • It is also approved for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status.